Inventory, Net in USD of ELITE PHARMACEUTICALS INC /NV/ from Q1 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Inventory, Net history and change rate from Q1 2011 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Inventory, Net for the quarter ending 30 Sep 2025 was $18,164,934.000, a 28.2% increase year-over-year.
Inventory, Net, Quarterly (USD)
Inventory, Net, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Inventory, Net (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $18,164,934 +$3,999,989 +28.2% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $19,356,728 +$5,525,410 +39.9% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $16,240,376 +$3,309,912 +25.6% 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 $20,157,890 +$5,832,849 +40.7% 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $14,164,945 -$1,059,439 -7% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $13,831,318 +$2,662,887 +23.8% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $12,930,464 +$3,379,748 +35.4% 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $14,325,041 +$5,723,183 +66.5% 31 Dec 2023 10-Q 14 Feb 2024
Q3 2023 $15,224,384 +$7,756,098 +1% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $11,168,431 +$3,551,268 +46.6% 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 $9,550,716 +$2,809,546 +41.7% 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $8,601,858 +$1,907,788 +28.5% 31 Dec 2022 10-Q 14 Feb 2023
Q3 2022 $7,468,286 +$922,628 +14.1% 30 Sep 2022 10-Q 14 Nov 2022
Q2 2022 $7,617,163 +$913,646 +13.6% 30 Jun 2022 10-Q 15 Aug 2022
Q1 2022 $6,741,170 +$1,728,268 +34.5% 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $6,694,070 +$1,892,063 +39.4% 31 Dec 2021 10-Q 14 Feb 2022
Q3 2021 $6,545,658 +$2,083,095 +46.7% 30 Sep 2021 10-Q 15 Nov 2021
Q2 2021 $6,703,517 +$1,137,114 +20.4% 30 Jun 2021 10-Q 16 Aug 2021
Q1 2021 $5,012,902 +$870,430 +21% 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $4,802,007 +$991,606 +26% 31 Dec 2020 10-Q 16 Feb 2021
Q3 2020 $4,462,563 +$730,341 +19.6% 30 Sep 2020 10-Q 16 Nov 2020
Q2 2020 $5,566,403 +$1,026,689 +22.6% 30 Jun 2020 10-Q 14 Aug 2020
Q1 2020 $4,142,472 -$373,251 -8.3% 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 $3,810,401 -$381,984 -9.1% 31 Dec 2019 10-Q 10 Feb 2020
Q3 2019 $3,732,222 -$753,720 -16.8% 30 Sep 2019 10-Q 12 Nov 2019
Q2 2019 $4,539,714 +$399,524 +9.6% 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 $4,515,723 -$382,278 -7.8% 31 Mar 2019 10-K 29 Jun 2020
Q4 2018 $4,192,385 -$1,106,558 -20.9% 31 Dec 2018 10-Q 11 Feb 2019
Q3 2018 $4,485,942 -$1,222,890 -21.4% 30 Sep 2018 10-Q 09 Nov 2018
Q2 2018 $4,140,190 -$1,750,078 -29.7% 30 Jun 2018 10-Q 09 Aug 2018
Q1 2018 $4,898,001 -$1,517,965 -23.7% 31 Mar 2018 10-K 21 Jun 2019
Q4 2017 $5,298,943 -$729,871 -12.1% 31 Dec 2017 10-Q 09 Feb 2018
Q3 2017 $5,708,832 +$73,297 +1.3% 30 Sep 2017 10-Q 09 Nov 2017
Q2 2017 $5,890,268 +$2,154,974 +57.7% 30 Jun 2017 10-Q 09 Aug 2017
Q1 2017 $6,415,966 +$3,122,237 +94.8% 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 $6,028,814 +$2,847,201 +89.5% 31 Dec 2016 10-Q 09 Feb 2017
Q3 2016 $5,635,535 +$2,282,222 +68.1% 30 Sep 2016 10-Q 09 Nov 2016
Q2 2016 $3,735,294 +$872,081 +30.5% 30 Jun 2016 10-Q 09 Aug 2016
Q1 2016 $3,293,729 +$261,727 +8.6% 31 Mar 2016 10-K 14 Jun 2017
Q4 2015 $3,181,613 +$318,000 +11.1% 31 Dec 2015 10-Q 09 Feb 2016
Q3 2015 $3,353,313 +$829,696 +32.9% 30 Sep 2015 10-Q 30 Dec 2015
Q2 2015 $2,863,213 +$337,298 +13.4% 30 Jun 2015 10-Q 30 Dec 2015
Q1 2015 $3,032,002 +$1,099,516 +56.9% 31 Mar 2015 10-K 15 Jun 2016
Q4 2014 $2,863,613 +$1,331,968 +87% 31 Dec 2014 10-Q 17 Feb 2015
Q3 2014 $2,523,617 +$803,944 +46.8% 30 Sep 2014 10-Q 14 Nov 2014
Q2 2014 $2,525,915 +$1,587,291 +1.7% 30 Jun 2014 10-Q 14 Aug 2014
Q1 2014 $1,932,486 +$574,340 +42.3% 31 Mar 2014 10-K 15 Jun 2015
Q4 2013 $1,531,645 +$547,214 +55.6% 31 Dec 2013 10-Q 14 Feb 2014
Q3 2013 $1,719,673 +$1,238,938 +2.6% 30 Sep 2013 10-Q 14 Nov 2013
Q2 2013 $938,624 +$575,659 +1.6% 30 Jun 2013 10-Q 14 Aug 2013
Q1 2013 $1,358,146 +$1,053,264 +3.5% 31 Mar 2013 10-K 30 Jun 2014
Q4 2012 $984,431 +$553,031 +1.3% 31 Dec 2012 10-Q 14 Feb 2013
Q3 2012 $480,735 +$98,496 +25.8% 30 Sep 2012 10-Q 14 Nov 2012
Q2 2012 $362,965 +$50,940 +16.3% 30 Jun 2012 10-Q 14 Aug 2012
Q1 2012 $304,882 -$311,480 -50.5% 31 Mar 2012 10-K 21 Jun 2013
Q4 2011 $431,400 31 Dec 2011 10-Q 14 Feb 2012
Q3 2011 $382,239 30 Sep 2011 10-Q 14 Nov 2011
Q2 2011 $312,025 30 Jun 2011 10-Q/A 19 Aug 2011
Q1 2011 $616,362 31 Mar 2011 10-K 29 Jun 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.